Kv1.3 Binding Immunoglobulins for Selective Ion Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting the Kv1.3 ion channel lack specificity and efficacy, particularly in modulating potassium ion efflux, and often compromise the protective immune response.
Innovation Solution
Development of immunoglobulin single variable domains that bind to the first extracellular loop (EL1) of the Kv1.3 channel, exhibiting improved selectivity and modulating activity, including partial or full blockade of Kv1.3 activity with high specificity and reduced potassium ion efflux from T-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to target Kv1.3 ion channel, then some level of channel modulation is achieved, but specificity and efficacy are insufficient and protective immune response is compromised
Solution Approach 1:
The patent targets a specific local region (first extracellular loop EL1) of the Kv1.3 ion channel with high specificity, rather than using non-specific therapeutic agents. This localized targeting approach enables precise modulation of Kv1.3 activity while preserving other immune functions, resolving the contradiction between achieving reliable channel blockade and maintaining protective immune response.
Solution Approach 2:
The invention achieves potent channel blockade with IC50 values in the nanomolar to picomolar range, representing a significant change in binding affinity parameter compared to current therapeutic agents. This enhanced specificity parameter allows effective Kv1.3 inhibition without the need for high doses that would compromise immune response.
2Reliability
If immunoglobulin single variable domains bind to EL1 of Kv1.3, then selectivity and modulation activity are improved, but complete blockade of potassium ion efflux is difficult to achieve
Solution Approach 1:
The patent combines multiple immunoglobulin single variable domains with different CDR3 sequences that all target the same EL1 epitope. This merging of multiple binding agents against a single target site achieves synergistic blockade efficacy, overcoming the limitation of individual domains while maintaining high selectivity for Kv1.3.
Solution Approach 2:
The invention creates a composite therapeutic approach using multiple V domains with identical CDR1 and CDR2 but varied CDR3 sequences, all binding to EL1. This composite strategy achieves complete or near-complete blockade of potassium ion efflux (reducing by at least 70%) while maintaining the selective advantage of EL1 targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoglobulin single variable domains achieve significant inhibition of Kv1.3 activity, reducing potassium ion efflux by at least 70% and demonstrating high specificity over other related Kv ion family members, with IC50 values as low as 10^-10 M, while maintaining immune response integrity.
Implementation Method 1
immunoglobulin single variable domains that bind to the first extracellular loop (EL1) of the Kv1.3 channel
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kvl.3.